Overview

Sunitinib Malate in Refractory Germ Cell Tumors

Status:
Terminated

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if Sutent® (sunitinib malate, SU011248) can control the disease in patients with germ cell tumors that are resistant to earlier treatment.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Pfizer

Treatments:

Sunitinib